• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Safety Profile of Upadacitinib in Psoriatic Arthritis: Integrated Analysis from Two Phase 3 Trials

    Author(s)
    Burmester, Gerd
    Winthrop, Kevin
    Nash, Peter
    Goupille, Philippe
    Azevedo, Valderilio F
    Salvarani, Carlo
    McCaskill, Reva M
    Liu, John
    Pierre-Louis, Bosny J
    Anderson, Jaclyn K
    Ruderman, Eric
    Griffith University Author(s)
    Nash, Peter
    Year published
    2021
    Metadata
    Show full item record
    Abstract
    Aim: Upadacitinib (UPA) has shown efficacy and safety in patients (pts) with active PsA in the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 clinical trials. We present the integrated safety data from the placebo (PBO)-controlled 24-week period of the clinical program. Methods: The SELECT-PsA program enrolled pts with prior inadequate response (IR) or intolerance to ≥1 non-biologic DMARD (non-bDMARD) and prior IR or intolerance to ≥1 bDMARD. Both trials evaluated PBO, UPA 15 mg once daily (QD; UPA15) and UPA 30 mg QD (UPA30); SELECT-PsA 1 also included the active comparator adalimumab (ADA). The number and percentage of pts with ...
    View more >
    Aim: Upadacitinib (UPA) has shown efficacy and safety in patients (pts) with active PsA in the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 clinical trials. We present the integrated safety data from the placebo (PBO)-controlled 24-week period of the clinical program. Methods: The SELECT-PsA program enrolled pts with prior inadequate response (IR) or intolerance to ≥1 non-biologic DMARD (non-bDMARD) and prior IR or intolerance to ≥1 bDMARD. Both trials evaluated PBO, UPA 15 mg once daily (QD; UPA15) and UPA 30 mg QD (UPA30); SELECT-PsA 1 also included the active comparator adalimumab (ADA). The number and percentage of pts with TEAEs through Week 24 are presented. Results: The rates of TEAEs, serious AEs, and AEs leading to study drug discontinuation (D/C) were similar with PBO and UPA15 and higher with UPA30. Rates of serious infection (SIs) and herpes zoster (HZ) were similar with PBO and UPA15 and higher with UPA30. The number of adjudicated major adverse cardiovascular events (MACE) and venous thromboembolic events (VTE) was < 0.5% for all arms, with similar rates reported with PBO, UPA15, and UPA30; all pts had at least one risk factor. VTEs included 1 deep vein thrombosis in PBO and 1 pulmonary embolism each in the two UPA arms. CPK elevations were reported more frequently in the UPA arms vs PBO and were mostly asymptomatic, and rarely led to study drug D/C; no rhabdomyolysis was reported. The safety profile was generally consistent between UPA15 and ADA, except for lower rates of HZ, anaemia, and lymphopaenia and higher rates of hepatic disorders and neutropaenia in the ADA arm. Conclusion: The safety profiles of UPA15 and ADA were generally consistent. The safety profile of UPA15 and UPA30 in PsA pts demonstrated consistent results compared to what has been observed with UPA in RA pts.
    View less >
    Conference Title
    Internal Medicine Journal
    Volume
    51
    Issue
    S2
    Publisher URI
    https://onlinelibrary.wiley.com/doi/10.1111/imj.15302
    Subject
    Cardiovascular medicine and haematology
    Clinical sciences
    Science & Technology
    Life Sciences & Biomedicine
    Medicine, General & Internal
    General & Internal Medicine
    Publication URI
    http://hdl.handle.net/10072/405122
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander